CTOs on the Move


 
Get the supplements, nutrient-dense and Earth-grown foods, and fitness equipment to achieve your next level of well-being and Total Human Optimization.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.onnit.com
  • 4401, Freidrich Lane
    Austin, TX USA 78744
  • Phone: 855.666.4899

Executives

Name Title Contact Details

Similar Companies

Dental Health Alliance

Dental Health Alliance is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TAMI North America

TAMI North America is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Altus Health

With personalized treatments and guidance from medical and athletic professionals, you can achieve your health and fitness goals at Altus.

The Integrated Health and Social Services University Network for West-Central Montreal

The Integrated Health and Social Services University Network for West-Central Montreal (CIUSSS West-Central Montreal) is one of the largest health and social services network in the Montreal area, regrouping over 20 establishments in the west end of Montreal and serving a population of nearly 345,000. We are making the difference, one person at a time. CIUSSS West-Central Montreal`s services and programs span the continuum of healthcare, from hospital to community integrated services to residential care. Our 9,000 employees, including 900 doctors, are guided by values of compassion, integrity and commitment to the quality of care. We are proud of our official bilingual status and the culturally rich identities of our sites. On top of clinical activities, research and teaching play an integral part in the CIUSSS West-Central Montreal network.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.